Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

W. Taal, H.M. Oosterkamp, A.M.E. Walenkamp, H.J. Dubbink, L.V. Beerepoot, M.C.J. Hanse, J. Buter, A.H. Honkoop, D. Boerman, F.Y.F. de Vos, W.N.M. Dinjens, R.H. Enting, M.J.B. Taphoorn, F.W.P.J. van den Berkmortel, R.L.H. Jansen, D. Brandsma, J.E.C. Bromberg, I. van Heuvel, R.M. Vernhout, B. van der HoltM.J. van den Bent

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)943-953
JournalLancet Oncology
Volume15
Issue number9
DOIs
Publication statusPublished - 2014

Cite this